Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe symbols : Bmrn save search
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
Published: 2023-09-15 (Crawled : 13:30) - prnewswire.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -0.34%
H: 2.01%
C: 0.89%
voxzogo europe chmp children achondroplasia positive treat
BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe
Published: 2023-08-30 (Crawled : 20:00) - prnewswire.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 0.65%
H: 0.64%
C: -3.22%
roctavian europe
MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic Diseases
Published: 2023-04-25 (Crawled : 13:20) - biospace.com/
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 0.2%
H: 0.43%
C: -0.81%
rare genetic research collaboration therapeutics platform
BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
Published: 2022-06-24 (Crawled : 12:00) - prnewswire.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
europe chmp positive therapy
BioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A at 15th Annual Congress of European Association for Haemophilia and Allied Disorders (EAHAD) 2-4 February
Published: 2022-02-04 (Crawled : 17:00) - prnewswire.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
europe order gene therapy presentation therapy phase 3 haemophilia
BioMarin Demonstrates Enduring Commitment to Advancing the Standard of Care in Hemophilia A at 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) February 2-4
Published: 2022-02-02 (Crawled : 22:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -3.07%
H: 1.15%
C: 0.75%
europe order haemophilia
European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Published: 2021-08-27 (Crawled : 13:00) - prnewswire.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 0.39%
H: 6.45%
C: 5.54%
treatment europe drop children growth voxzogo achondroplasia
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Published: 2021-07-15 (Crawled : 13:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -0.36%
H: 0.76%
C: 0.23%
europe authorized application
BioMarin Resubmits Marketing Authorization Application (MAA) to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Published: 2021-06-28 (Crawled : 13:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 1.18%
H: 0.63%
C: -1.59%
europe authorized application
BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Published: 2021-06-25 (Crawled : 12:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 0.66%
H: 1.39%
C: 0.55%
treatment europe drop positive children growth chmp achondroplasia
European Medicines Agency Grants BioMarin's Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A
Published: 2021-05-24 (Crawled : 13:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 0.67%
H: 0.36%
C: -1.36%
treatment europe granted grant
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.